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Abstract
West Nile virus (WNV), a mosquito-borne single-stranded RNA flavivirus, can cause significant human morbidity and mortality.
Our data show that interleukin-10 (IL-10) is dramatically elevated both in vitro and in vivo following WNV infection. Con-
sistent with an etiologic role of IL-10 in WNV pathogenesis, we find that WNV infection is markedly diminished in IL-10 deficient
(IL-10
2/2) mice, and pharmacologic blockade of IL-10 signaling by IL-10 neutralizing antibody increases survival of WNV-infected
mice. Increased production of antiviral cytokines in IL-10
2/2 mice is associated with more efficient control of WNV infection.
Moreover, CD4
+T cells produce copious amountsof IL-10, and may be an important cellular sourceof IL-10 during WNV infection
in vivo. In conclusion, IL-10 signaling plays a negative role in immunity against WNV infection, and blockade of IL-10 signaling by
genetic or pharmacologic means helps to control viral infection, suggesting a novel anti-WNV therapeutic strategy.
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Introduction
WNV has caused severe morbidi t ya n dm o r t a l i t yi nb o t h
animals and humans since it first appeared in North America in
1999. WNV is maintained in an enzootic cycle between
mosquitoes and birds; but humans, horses and other mammals
can be inadvertently infected by mosquitoes that carry the virus.
Although most human infections are asymptomatic, the elderly
and individuals with a compromised immune system are
particularly susceptible to life-threatening neurologic disease
[1]. Viral pathogenesis is not completely understood, and a
vaccine or specific therapy has not yet been approved for use in
humans [2]. Experimental mice infected with WNV develop a
systemic infection that results in encephalitis and death, thereby
mimicking human neuroinvasive disease and providing a
valuable model system within which to study viral pathogenesis
and immunity.
Mammalian T helper 1 (Th1) cytokine responses are essential
for eradicating invading intracellular pathogens. However, if these
responses are too strong, bystander effects may damage the host.
Interleukin-10 (IL-10), a pleiotropic cytokine, plays a crucial
immunosuppressive role during excessive Th1 responses, and can
thereby protect the host from potentially damaging immunopa-
thology [3–5]. However, excessive IL-10 production suppresses
host immune responses and can inadvertently facilitate the ability
of intracellular pathogens to escape host innate immune defenses.
Epstein-Barr virus (EBV) takes advantage of the immunomodu-
latory effects of IL-10 by expressing a viral homolog of IL-10
during infections [6]. In addition, recent studies showed that
lymphocytic choriomeningitis virus (LCMV) clone 13 elicits high
levels of IL-10 production from the infected host, thereby resulting
in exhaustion of virus-specific T cells and viral persistence [7–9].
Interestingly, neutralization of IL-10 during persistent viral
infection leads to recovery of virus-specific T cell responses and
reduction of viral load, suggesting a potential therapy to restore T
cell function and prevent viral persistence [7,8].
Type I Interferon (IFN) and Th1 cytokines, including IFN-c,
provide immediate defense against WNV replication and dissemina-
tion [10–14]. Cellular immunity, including CD4
+ [15,16], CD8
+ T
cell [17–21] and cd T cell responses [22–24], also participate in host
recovery from WNV infection. IL-10 [3] and other regulatory
cytokines, such as IL-4 [25–28] and IL-13 [29,30] have been
documented to suppress Th1 responses. The role of these regulatory
cytokines in modulating Th1 responses during WNV pathogenesis is,
however, not completely understood. In the current study, we
i n v e s t i g a t e dt h er o l eo fI L - 1 0i nW N Vi n f e c t i o n ,a n do u rr e s u l t s
suggest a promising therapeutic strategy to combat WNV infection
through blockade of IL-10 signaling.
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Expression of IL-10 is dramatically increased after WNV
infection
To study host immune responses to WNVinfection, we performed
cytokine expression polymerasechain reaction (PCR) arrays inwhich
cytokine expression profiles were analyzed in thioglycollate-elicited
peritoneal macrophages from C57BL/6 mice after WNV infection
(multiplicity of infection [MOI]=1). We observed that IL-10
expression was up-regulated 4- fold at 5 h and 90-fold at 24 h
post-infection (p.i.), while expression of IL-4, IL-13 and another
immunosuppressive cytokine, TGF-b, were not significantly altered at
both time points (data not shown). To confirm this finding, we
measured IL-10 mRNA by reverse transcription quantitative real-
time PCR (Q-PCR) and quantified secreted IL-10 protein in cell
culture media from primary cultures of WNV-infected macrophages
by ELISA. Both Q-PCR and ELISA results confirmed that IL-10
mRNA and IL-10 protein were markedly up-regulated after WNV
infection in vitro (Figure 1 A and B). To further evaluate expression
kinetics of IL-10 in vivo, we intraperitoneally (i.p.) infected a group of
C57BL/6 mice with 2,000 plaque forming units (pfu) of WNV
corresponding to a dose at which approximately 50% of wild-type
(C57BL/6J) animals survive (LD50) [31–33] and measured time-
dependent IL-10 secretion in plasmaby ELISA (Figure1 C).Results
showed that IL-10 production began to increase in plasma as early as
6 h p.i. and reached approximately 18-fold at day 5 (120 h)
compared to baseline (before infection, 0 h). These data raise the
possibility that IL-10 may play a role in modulating immune
responses during WNV infection.
Author Summary
West Nile virus (WNV), a mosquito-transmitted RNA virus, is
a worldwide cause of severe human and animal infection.
Mammalian host immune responses to WNV infection are
not completely understood and a vaccine or specific
therapy is unavailable for use in humans. In the present
study, we investigated the putative regulatory role of
interleukin-10 (IL-10) during WNV infection in mice. We
found that IL-10 signaling facilitates WNV infection and
suppresses antiviral cytokine production in response to
viral infection. Interestingly, blockade of IL-10 signaling by
IL-10 neutralizing antibody increases survival of WNV-
infected mice, suggesting a potentially novel therapeutic
strategy to combat WNV infection. In addition, we found
that CD4
+ T cells produce a significant amount of IL-10
during WNV infection, providing a more accurate cellular
target for IL-10 signaling inhibition. IL-10 also plays a
critical role in suppression of excessive inflammation and
immunopathology caused by autoimmune diseases or
host immune system responses to infections; therefore,
safety and efficacy of IL-10 signaling blockade as a
therapeutic strategy against WNV infection deserves
consideration.
Figure 1. IL-10 expression is elevated in vitro and in vivo upon WNV infection. Thioglycollate-elicited peritoneal macrophages from C57BL/6
mice were infected with WNV (MOI=1) for 24 hours. (A), IL-10 mRNA was measured by Q-PCR and normalized to mouse b-actin (Actb; unitless ratio+1
SEM). (B), ELISA results are shown for IL-10 protein (pg/ml) in the media. (C), Plasma was prepared at selected time points from C57BL/6 mice infected
with WNV (LD50), and IL-10 (pg/ml) was measured by ELISA. * p,0.001.
doi:10.1371/journal.ppat.1000610.g001
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To evaluate a putative role for IL-10 in WNV pathogenesis, we
challenged IL-10
2/2 mice with an LD50 dose of WNV via an i.p.
route of administration [33,34]. Mice were monitored twice daily for
morbidity and mortality for three weeks. Q-PCR designed to
measure WNV envelope gene (WNVE) revealed 2–3 fold reduced
WNV RNA in blood samples from IL-10
2/2 mice compared to
control mice at days 1 and 3 p.i. (p,0.05, Figure 2 A). Plaque
formation assays were also performed to measure infectious viral
particles in plasma samples. Consistent with Q-PCR data, plaque
formation assay results showed that IL-10
2/2 mice had a similar
magnitude of lower viral burden compared with control mice (data
not shown). In selected experiments, we randomly sacrificed half the
numberofmicetocollectspleensamplesatday3andtocollectbrains
at day 7, while the remaining mice were observed for survival
analysis. Total RNA extracted from spleen and brain hemispheres
was used for Q-PCR analysis of WNV burden. Contralateral brain
hemispheres were fixed in 4% paraformaldehyde (PFA) for
histological analysis. Markedly less viral RNA was present in the
spleens and brains of IL-10
2/2 mice vs. wild-type mice (p,0.05,
Figure 2 B). Confocal microscopy results were consistent with brain
Q-PCR data in that IL-10
2/2 mice had little evidence of virus in the
olfactory bulb (OB), cerebral cortex, striatum, cerebellum and
brainstem, whereas WNV was readily detected in similar brain
regions of control mice on day 7 p.i. (Figure 2 C and Figure S1).
Co-immunostaining with the neuronal marker microtubule-associat-
ed protein 2 (MAP2) revealed that most of the infected cells were
neurons (Figure 2 C and Figure S1). In addition, a higher number
of CD45
+ leukocytes infiltrated into brains of wild-type mice as
compared to IL-10
2/2 mice (Figure 2 C). Similar results were
observed when immunostaining for CD11b, a marker for macro-
phages/microglia (Figure S1). The survival ratio of IL-10
2/2 mice
(70.0%) was significantly higher than that of wild-type mice (33.3%)
(p,0.01, Figure 2 D). As virus inoculation routes may alter host
immune responses, we also challenged IL-10
2/2 mice with WNV via
footpad inoculation (100 pfu) route and performed survival analysis.
Similar to intraperitoneal inoculation, IL-10
2/2 mice also had
increased survival after footpad infection (Figure 2 E). Collectively,
viral burden and survival analyses demonstrate that mice deficient in
IL-10 have increased resistance to WNV infection, suggesting that IL-
10 signaling facilitates WNV pathogenesis.
We further tested this hypothesis by taking a pharmacological
approach to interrupt IL-10 signaling. Specifically, we systemically
administered anti-IL-10 receptor monoclonal antibody (aIL-10r
mAb) to block IL-10 signaling. We injected aIL-10r mAb or
isotype-matched control IgG (i.p.) on day 1 prior to WNV
infection. Mice were challenged with 2,000 pfu (i.p.) or 100 pfu
(footpad inoculation) of WNV. Blood samples were collected from
the mice infected intraperitoneally on day 3 (p.i.) for WNV burden
Q-PCR measurement. Q-PCR results showed a trend toward
reduced viral burden in blood of mice treated with aIL-10r mAb
prior to intraperitoneal WNV infection (Figure 3 A, p=0.07).
Survival analysis indicated that mice treated with aIL-10r mAb
had increased survival compared to mice injected with isotype-
matched IgG (p,0.05, Figure 3 B and C). These data further
confirm that IL-10 signaling facilitates WNV infection and
promotion of lethal encephalitis.
IL-10 signaling suppresses antiviral cytokine production
in WNV-challenged immune cells and mice
We have previously shown that macrophages can be infected with
WNV, and are likely an important target cell in WNV pathogenesis
[33,34]. To dissect the mechanisms underlying how IL-10 signaling
facilitates WNV infection, we measured cytokine expression in
macrophages from IL-10
2/2 and wild-type mice upon virus infection
in vitro. We infected thioglycollate-elicited macrophages obtained
from peritoneal lavage with WNV, and quantified cytokines by
ELISA or Q-PCR at selected time points. Consistent with a stronger
anti-viral response, results showed that WNV-infected macrophages
from IL-10
2/2 mice produced more TNF-a,I F N - a,I F N - b and IL-
12/23 p40 than wild-type cells (Figure 4 A–D). The spleen is a
WNV target organ, and splenic WNV infection is thought to be
involved in host immune defense against infection [15,35]. We
therefore assessed cytokine production in splenic cells isolated from
naı ¨ve and WNV-infected mice. We infected naı ¨ve splenocytes with
WNV (MOI=0.5) and measured production of IL-12/23 p40 and
IFN-c by ELISA at selected time points. Splenocytes from IL-10
2/2
mice produced elevated IL-12/23 p40 compared to splenocytes from
w i l d - t y p em i c e( Figure 4 E), while IFN-c production was not
detected by ELISA in either group. We also quantified cytokine
production from splenocytes isolated on day 3 p.i.. Specifically, we
stimulated splenocytes with WNV MHC class I epitope peptide
NS4b [36,37] ex vivo for 24 or 48 h. ELISA results showed that TNF-
a and IL-12/23 p40 were significantly elevated in splenocytes from
IL-10
2/2 mice (Figure 4 F and G), while IFN-c production was
undetectable. In addition, we evaluated cytokine secretion in
peripheral blood of IL-10
2/2 compared to wild-type mice during
WNV infection (LD50, i.p.) by ELISA or Q-PCR. ELISA results
showed that IL-12/23 p40 and TNF-a production in plasma from
IL-10
2/2 mice was higher than wild-type mice plasma samples on
day 2 after infection (Figure 4 H and I). Because IFN protein
production in plasma was below the detection level of ELISA, we
measuredIFN-c mRNAlevelsinbloodbyQ-PCR.TheQ-PCRdata
show that expression of IFN-c in blood of IL-10
2/2 mice trended
toward significantly lower than wild-type mice in all the selected time
points, and reached statistical significance on day 3 p.i. (Figure 4 J).
Collectively, these data suggest that genetic blockade of IL-10
signaling results in a significant elevation of type I IFN and
proinflammatory cytokines in macrophages, splenic cells and
peripheral blood during WNV infection.
Increased type I IFN and innate immune proinflammatory
cytokines might be expected to contribute to efficient control of
WNV infection after IL-10 signaling blockade. To assess this, we
evaluated WNV replication in macrophages from IL-10
2/2 and
wild-type mice in vitro by Q-PCR and plaque formation assay.
Both assays indicated lower viral burden in macrophages from
IL-10
2/2 vs. wild-type mice, showing increased resistance of IL-
10
2/2 macrophages to direct WNV infection (Figure 5 A and B).
To further assess whether type I IFN plays an antiviral role in
macrophages from IL-10
2/2 mice, we incubated macrophages
with anti-IFN-a/b receptor neutralizing mAb and measured viral
replication by Q-PCR after infection with WNV (MOI=1)
(Figure 5 C). Q-PCR results showed that neutralizing antibody
treatment partially restored WNV replication in macrophages
from IL-10
2/2 mice. We next measured type I IFN activity in the
media of naı ¨ve splenic cells that were infected with WNV
(MOI=0.5) using a virus protection assay (murine encephalo-
myocarditis virus [EMCV] bioassay). These results suggested that
splenic cells from IL-10
2/2 mice secrete more type I IFN
compared to wild-type mice after WNV infection in vitro (Figure 5
D). The results of the antibody treatment and bioassay
experiments indicated that type I IFN production limits viral
replication in vitro in WNV-infected IL-10
2/2 immune cells in vitro.
To determine if something similar may occur in vivo, we measured
type I IFN activity in plasma from wild-type and IL-10
2/2 mice
by EMCV bioassay. Results showed similar type I IFN activity at
days 1 and 5 (p.0.1), while at day 3, plasma from IL-10
2/2 mice
had significantly reduced activity compared with plasma from WT
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2/2 mice were i.p. challenged with WNV (LD50). (A), Q-PCR
was performed for WNVE in peripheral blood on days 1 (IL-10
2/2 mice, n=14 and WT mice, n=10) and 3 (IL-10
2/2 mice, n=14 and WT mice, n=9)
p.i.. (B), Q-PCR was performed for WNVE in spleens on day 3 (n=5/group) and brains on day 7 (IL-10
2/2 mice, n=7 and WT mice, n=9) p.i.. (C),
Perfused brains were isolated on day 7 p.i., and WNV antigen (green signal), CD45 (leukocyte common antigen, red signal) and neurons (MAP2, blue
signal) were detected by confocal microscopy (OB: Olfactory bulb). These images represent 9 mice per group in 3 independent experiments. (D),
Kaplan-Meier survival analysis of IL-10
2/2 and WT mice after i.p. inoculation of WNV (n=30/group). Data shown are pooled from 3 independent
experiments. (E), Survival analysis after WNV inoculation by footpad injection (IL-10
2/2 mice, n=8 and WT mice n=10). Data (means+1 SEM) are
pooled results from 2–3 similar independent experiments. *p,0.05 and **p,0.01, compared to control mice.
doi:10.1371/journal.ppat.1000610.g002
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+ T cells play an important role in recovery of
WNV infection in the mouse model [15,17–21]. In addition, host IL-
10 expression may result in CD4
+ and CD8
+ Tc e l le x h a u s t i o ni n
chronic viral infections [7–9]. We investigated whether CD4
+ and
CD8




2/2 and wild-type control mice and stimulated with PMA or
peptide NS4b for 6 h. Total splenic cells were stained for CD4 and
CD8 surface markers and for intracellular IFN-c.F l o wc y t o m e t r y





+ cellswere significantlyreduced in IL-10
2/2 mice (Figure 6 A–C).
T h e s er e s u l t sa r ec o n s i s t e n tw i t hI F N - c in blood of IL-10
2/2 mice,
which trended toward reduced compared with wild-type mice
(Figure4 J).Thesedata suggest that IFN-cdoes not play a dominant
role in mitigation of WNV infection in IL-10
2/2 mice. To exclude
the possibility that T cells from IL-10
2/2 mice may not be as
responsive as those that from wild-type mice, we stimulated
spenocytes from naı ¨ve mice with PMA for 6 h and stained for
CD4 and CD8 surface markers and for intracellular IFN-c.T h e
results show that CD4
+ and CD8
+ T cells from naı ¨ve IL-10
2/2 mice
produce more INF-c than those from wild-type mice (Figure 6 D),
suggesting that response to PMA stimulation is intact in T cells from
IL-10
2/2 mice. Collectively, these data suggest that elevated WNV-
induced antiviral cytokines in IL-10
2/2 immune cells but not IFN-c
production in CD4
+ and CD8
+ T cells likely serve to limit viral
replication in IL-10
2/2 mice.
IL-10 neutralizing mAb is protective after lethal WNV
infection
As blockade of IL-10 signaling via genetic means leads to
enhanced anti-viral immunity mitigating WNV infection, we
wanted to assess the effect of pharmacological IL-10 blockade on
lethal WNV encephalitis. We used a monoclonal antibody directed
against IL-10 (anti-IL-10 mAb) to neutralize IL-10 in vivo following
WNV infection. Because a treatment course for WNV disease
would begin after exposure to the virus, we first infected mice with
WNV (LD50, i.p.) and followed by treatment with two daily i.p.
doses of anti-IL-10 mAb or isotype-matched IgG control antibody.
Antibodies were injected starting on day 2 or day 4 p.i. Survival
curves indicate that anti-IL-10 antibody significantly increases
survival of WNV-infected mice when administered as late as day 2
p.i. (p,0.05, Figure 7). Yet, this effect is abolished when the
neutralizing antibody is administrated on day 4 p.i., as survival
rates are similar between the two groups (data not shown).
CD4
+ T cells produce copious amounts of IL-10 in vivo
during WNV infection
IL-10 is provided by various cellular sources in different disease
models [38–40]. A better understanding of the cellular sources of
Figure 3. Prophylactic blockade of IL-10 signaling increases survival of WNV-infected mice. A group of C57BL6 mice were i.p.
administered anti-IL-10 receptor monoclonal antibody (aIL-10r mAb) or isotype-matched IgG control antibody one day before challenge with WNV.
(A), Viral load was measured in blood on day 3 p.i. by Q-PCR (p=0.07, LD50, i.p..); (B–C), Kaplan-Meier survival analysis showed significant differences
between the aIL-10r mAb and isotype-matched IgG treated group. (B, i.p. inoculation [LD50], n=17/group, data were pooled from 3 independent
experiments; C, footpad inoculation [100 pfu], n=10/group). *p,0.05, compared to control mice.
doi:10.1371/journal.ppat.1000610.g003
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PLoS Pathogens | www.plospathogens.org 5 October 2009 | Volume 5 | Issue 10 | e1000610Figure 4. Immune cells and mice deficient in IL-10 produce more antiviral cytokines. Thioglycollate elicited peritoneal macrophages from
IL-10
2/2 and wild-type (WT) mice were challenged with WNV (MOI=1) or PBS (mock infection) for 24 hours. (A–C), TNF-a, IFN-a and IFN-b were
measured in media by ELISA. (D), Total RNA from macrophages was analyzed for IL-12/23 p40 mRNA expression by Q-PCR. The data are normalized to
mouse b-actin mRNA and are expressed as the relative fold increase over normalized RNA from mock controls. (E), Splenocytes isolated from naı ¨ve IL-
10
2/2and WT mice were infected with WNV (MOI=0.5), and IL-12/23 p40 production was measured in media by ELISA. (F and G) Splenocytes isolated
from WNV-infected IL-10
2/2 or WT mice on day 3 p.i. (LD50, i.p.) were stimulated by WNV NS4b peptide (1610
6 cells, 1.0 mg/ml) for 24 or 48 hours.
TNF-a (F) and IL-12/23 p40 (G) were measured in media by ELISA. (H and I) WT and IL-10
2/2 mice were i.p. challenged with WNV (LD50) and bled on
day 1, day 2 and 3 p.i., and IL-12/23 p40 (H) and TNF-a (I) were measured in plasma by ELISA. (J), Expression of IFN-c (Ifng) was measured in peripheral
blood by Q-PCR. These data are representative of two independent experiments, with animal numbers $4 per group. *p,0.05, **p,0.01 and
***p,0.001.
doi:10.1371/journal.ppat.1000610.g004
Blocking IL-10 Signaling Controls WNV Infection
PLoS Pathogens | www.plospathogens.org 6 October 2009 | Volume 5 | Issue 10 | e1000610IL-10 and mechanisms of induction is required to definean effective
immunotherapeutic strategy aimed at IL-10. To identify the cellular
source of IL-10 in vivo during WNV infection, we used IL-10-GFP
reporter knock-in tiger mice, in which an internal ribosome entry site
GFP element was inserted into the 39 region of the IL-10 gene.
During characterization of these mice, GFP and IL-10 expression
werefoundto becloselycorrelated inallcellpopulations tested [40],
thus allowing the identification of IL-10-producing cells ex vivo
without subsequent manipulation. We examined splenocytes
isolated from tiger mice for expression of GFP and various cell-
surface markers on selected days after WNV infection. No
significant GFP production from macrophages (CD11b
+), dendritic
cells (CD11c
+), B cells (CD19
+), or non-CD4
+ T cells (CD3
+CD4
2)
was observed at any selected time points (Figure 8 A). However, a




+), which peaked on day 5 post infection (Figure 8 A).
Thistime course of IL-10 inductionin CD3
+CD4
+ cells is consistent
with IL-10 production in plasma of wild-type mice during WNV
infection(Figure1 C). Thesedata suggestthatCD4
+T cellssecrete
copious amounts of IL-10 during WNV infection in mice.
To further confirm this conclusion, we reconstituted RAG1
2/2
mice that lack T and B cells with naı ¨ve CD4
+ T cells from wild-
Figure 5. Type I IFN is associated with inhibition of WNV infectivity in vitro. (A–B) One million thioglycollate-elicited peritoneal
macrophages isolated from IL-10
2/2 and WT mice were infected with WNV (MOI=1) for 24 hours. (A), WNVE was measured in macrophages by Q-PCR
and (B) viral load was measured in media by plaque formation assay. (C), Macrophages from IL-10
2/2 mice were treated with or without (mock)
20 mg/ml of either normal rabbit IgGs or rabbit anti-IFNa/bR1 IgGs (R&D Biosystems) for 2 h followed by WNV infection (MOI=1) for 24 h. WNVE was
measured in macrophages by Q-PCR. (D), Splenic cells isolated from naı ¨ve WT and IL-10
2/2 mice were infected with WNV (MOI=0.5). Type I IFN level
in the medium was measured by IFN bioassay. (E), WT and IL-10
2/2 mice were inoculated with WNV (LD50, i.p.) and type I IFN level was measured by
IFN bioassay. *p,0.05 and **p,0.01.
doi:10.1371/journal.ppat.1000610.g005
Blocking IL-10 Signaling Controls WNV Infection
PLoS Pathogens | www.plospathogens.org 7 October 2009 | Volume 5 | Issue 10 | e1000610type or IL-10
2/2 mice or PBS (cell-free control) on day 1 prior to
WNV infection (LD50, i.p.). We subsequently measured IL-10
levels in plasma by ELISA at serial time points after infection.
Results showed that RAG1
2/2 mice reconstituted with CD4
+ T
cells from wild-type mice produced significantly higher amounts of
IL-10 than mice reconstituted with PBS or CD4
+ T cells from IL-
10
2/2 mice, providing definitive evidence that CD4
+ T cells
produce a significant amount IL-10 during WNV infection in mice
(Figure 8 B). It is worth noting that IL-10 was also detected in
plasma of the RAG1
2/2 mice reconstituted with PBS or CD4
+ T
cells from IL-10
2/2 mice, albeit at lower levels (Figure 8 B),
suggesting that cells other than CD4
+ T cells (such as
macrophages) play a certain but subdominant role in secreting
IL-10 during WNV infection in vivo. Therefore, these data confirm
that CD4
+ T cells produce a significant amount, but not all, of the
IL-10 in the murine WNV infection paradigm.
Discussion
StudiesonhostimmuneresponsestoWNVinfectionwillnotonly
result in a better understanding of viral pathogenesis, but may also
lead to novel immunotherapeutic strategies against viral infection.
IL-10 plays an immunosuppressive role through interaction
between antigen presenting cells and T cells [3,41,42]. IL-10 was
also found to induce T cell exhaustion during chronic viral
infections [7,8]. Systemic IL-10 production is increased in various
human chronic viral infections, such as hepatitis C virus [43,44],
human immunodeficiency virus [45,46] and hepatitis B virus [47].
Studies demonstrate that the IL-10/IL-10R pathway plays a key
role in the establishment of chronic LCMV persistent infection
[7,8]. Blockade of IL-10 signaling converts a chronic LCMV
infection into a rapidly controlled acute viral infection and prevents
functional exhaustion of memory T cells [7,8]. Further, a recent
Figure 6. CD4
+ and CD8
+ T cells deficient in IL-10 produce less IFN-c. (A–C) IL-10
2/2 and wild-type (WT) mice were i.p. challenged with WNV
(LD50). On day 7, mice were euthanized and splenocytes were isolated and stimulated with PMA or WNV NS4b peptide for 6 hours. Flow cytometry
analysis of IFN-c-producing CD8
+ T cells after stimulation with (A) PMA or (B) with WNV NS4b peptide was then carried out. (C), Flow cytometry
analysis of IFN-c producing CD4
+ T cells after stimulation with PMA is shown. These data represent two independent experiments (n=4/group). (D),
Splenocytes were isolated from naı ¨ve IL-10
2/2 and WT mice and stimulated with PMA for 6 hours. Flow cytometry analysis of IFN-c-producing CD4
+
and CD8
+ T cells is shown (n=3/group). * p,0.05 and **p,0.01.
doi:10.1371/journal.ppat.1000610.g006
Figure 7. Pharmacologic neutralization of IL-10 increases
survival of WNV-infected mice. Wild-type (WT) mice were i.p.
challenged with WNV (LD50). Mice received two i.p. injections of anti-IL-
10 monoclonal antibody (aIL-10 mAb, 200 mg/dose) or isotype control
IgG on day 2 and day 3 p.i. (p,0.05, n=15/group). Data were pooled
from three independent experiments. * p,0.05.
doi:10.1371/journal.ppat.1000610.g007
Blocking IL-10 Signaling Controls WNV Infection
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+ T cells produce copious amounts of IL-10 in vivo during WNV infection. GFP gene knock-in tiger and wild-type (WT, C57BL/
6) mice were i.p. challenged with WNV (LD50). Splenocytes isolated from WNV-infected tiger mice at selected time points p.i. were stained for surface
markers (day 0, uninfected splenocytes). GFP was used as a surrogate for IL-10 expression, and analyzed by flow cytometry. (A), Percentages of GFP
positive cells are shown within CD11b
+ (macrophages), CD11c
+ (dendritic cells), CD19
+ (B cells), non-CD4
+ (CD3
+CD4




cells populations. Dot-plot figures are representative of at least two independent experiments (n$2 for each experiment). (B), RAG1
2/2 mice were
reconstituted with CD4
+ T cells from naı ¨ve WT or IL-10
2/2 mice (1610
7 cells/mouse) or with PBS as control one day prior to WNV challenge (LD50, i.p.).
Mice were bled at selected time points and IL-10 production was measured in plasma by ELISA (**p,0.01, RAG1
2/2 mice reconstituted with CD4
+ T
cells from WT mice were compared to control mice, n$3/group).
doi:10.1371/journal.ppat.1000610.g008
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T cell response in an LCMVmouse model [48]. Interestingly, IL-10
production correlates directly with plasma HIV viral load and
inversely with CD4 cell counts [49].
In this study, we observed that IL-10 expression was
dramatically up-regulated in vitro and in vivo in murine plasma
during WNV infection, raising the possibility that IL-10 plays a
significant role in modulating host immune responses to WNV
infection. Through evaluation of WNV infection in IL-10
2/2 mice
and in wild-type mice that were administered anti-IL-10r mAb or
IL-10 neutralizing antibody to temporally block IL-10 signaling,
we found that IL-10 signaling facilitates WNV infectivity and
lethal encephalitis. WNV is a neuroinvasive virus that develops
low viremia in mice by replicating in peripheral organs including
spleen, and then infecting neurons causing meningitis and lethal
encephalitis in mice [31,34,50]. WNV is most often cleared from
blood and peripheral organs between one and two weeks p.i.. In
IL-10
2/2 mice, WNV load was significantly reduced in the blood
and spleen, suggesting that viral replication was efficiently
inhibited in the periphery. Consequently, the likelihood that the
virus would infect neurons was greatly reduced. We also
performed direct intracranial injection of WNV into wild-type
vs. IL-10
2/2 mice and evaluated survival. We did not detect a
difference using this route of infection (data not shown), suggesting
that IL-10 deficiency promotes WNV clearance at the level of the
periphery as opposed to the brain.
We next dissected the mechanisms by which IL-10 signaling
facilitates WNV infectivity. IL-10 suppresses Th1 responses that
are essential to restrict intracellular pathogens [3,41,42], and
previous studies suggested that IFN and proinflammatory cytokine
responses are important in anti-WNV immunity [11,14,51–53].
Consistent with this notion, we found that these antiviral cytokines
were increased in IL-10
2/2 macrophages, splenocytes and mouse
blood. Macrophages not only produce type I IFN, proinflamma-
tory cytokines and IL-10 upon WNV infection, but they can also
be directly infected by WNV. Interestingly, we noted MOI-
dependent increases in IL-10 production from wild-type macro-
phages (MOIs from 0.01 to 1.0), supporting the notion that
macrophage IL-10 production is directly correlated with viral
abundance. We confirmed that increased abundance of type I IFN
and proinflammatory cytokines were associated with inhibition of
WNV replication in IL-10
2/2 macrophages, and this inhibitory
effect was significantly reversed by antagonistic IFN-a/b receptor
antibodies. In addition, EMCV bioassay results demonstrated that
splenic cells isolated from IL-10
2/2 mice produced more type I
IFN upon WNV infection. These data are in line with the notion
that type I IFN plays an antiviral role in IL-10
2/2 immune cells in
vitro. However, a lower type I IFN activity level in plasma from IL-
10
2/2 mice compared with wild-type mice at day 3 p.i. was
detected by EMCV bioassay (Figure 5 E). This may be resolved
by the following reasoning. It is possible that higher viral burden in
wild-type mice (Figure 2 A) stimulates wild-type compared with
IL-10
2/2 immune cells to produce more type I IFN. This response
may be especially evident in the early phase of infection, because
at this stage production of regulatory cytokines (such as IL-10)
occurs at relatively low levels (Figure 1 C).
Studies on infections of bacteria, protozoa and some viruses
suggest that expression of IFN-c is up-regulated and participates in
controlling infection in the absence of IL-10 signaling [42,54,55].
The ability of IL-10 to down-regulate IFN-c production is a
consequence of its abilityto inhibit accessory cell function, including
production of cytokines (such as TNF-a and IL-12) and expression
of costimulatory molecules that are necessary for optimal stimula-
tion of T cells [56–59]. In our WNV model, we found that IFN-c
was not inducible in IL-10
2/2 immune cells or mice during WNV
infection. Studies in chronic infection models have shown that host
IL-10 production results in exhaustion of virus-specific T cells and
reduction of IFN-c expression [7–9]. We next examined IFN-c
expression on T cells by flow cytometry analysis during WNV
infection in IL-10
2/2 mice on day 7 p.i.. Results showed that the
frequency of IFN-c-producing CD4
+ and CD8
+ T cells was
remarkably lower in IL-10
2/2 than in wild-type mice (Figure 6
A–C). Consistently, IFN-c expression in blood from IL-10
2/2 mice
trended toward reduced from day 1 to day 3 p.i. (Figure 4 J). In IL-
10
2/2 mice, viral replication was significantly inhibited following
infection (Figure 2 A and B), indicating that IFN-c is dispensable
for controlling WNV infection in the model of IL-10
2/2 mice,
particularly during the early stage of infection.
In a previous study, TNF-a was shown to participate WNV
control in mouse models [60], and we observed that TNF-a
expression was up-regulated in IL-10
2/2 mice after WNV
infection. It is worth noting that TNF-a has also been shown to
increase permeability of the blood-brain-barrier (BBB) during
WNV infection [34]. There are a number of variables, including
the roles of TNF-a in anti-viral immunity independent of a role in
WNV BBB permeabilization, the relative importance of WNV
BBB permeability at early vs. later stages of infection, and whether
WNV entry into the brain via the BBB (as opposed to indirect
brain entry via brain penetration of infected leukocytes [34]) is a
critical pathway for brain infection and subsequent encephalitis,
that are dynamically at play during WNV infection [32,34,61–63].
These variables make direct determination of the contribution of
WNV-induced TNF-a expression in BBB permeability complex
and difficult to determine in our IL-10
2/2 WNV infection system.
We did not examine BBB permeability during WNV infection in
the present study because viral replication is significantly inhibited
in the periphery of IL-10
2/2 mice and the likelihood that WNV
would infect neurons is therefore correspondingly low. Thus, it
does not appear to be necessary to invoke a BBB permeability
hypothesis to explain our current results.
Upon viral infection, host innate immune sensors, including
Toll-like receptors, double-stranded RNA-activated protein kinase
(PKR), retinoic-acid-inducible protein I (RIG-I) and melanoma-
differentiation-associated gene 5 (MDA-5), can be activated to
produce type I IFNs and cytokines that limit viral replication and
dissemination. In the majority of human infections, WNV is
controlled and cleared by anti-viral immune responses before the
virus invades the central nervous system. However, for the elderly
and immunocompromised patients, for whom innate immune
responses are too weak or impaired to efficiently control WNV
infection, life-threatening neuroinvasive disease may result. In the
present study, we found that IL-10 inhibits host innate immune
responses during WNV infection. Importantly, blockade of IL-10
signaling through administration of neutralizing IL-10 antibody
was able to partially protect WNV-infected mice from death,
suggesting a promising immunotherapeutic strategy. The thera-
peutic effect of neutralizing IL-10 antibody was significant when
administered as late as day 2 p.i., and it is possible that its efficacy
may be extended by using higher doses of IL-10 signaling blocking
antibodies or small molecule compounds that inhibit the IL-10
signaling pathway. Blocking IL-10 signaling to stimulate host
immune responses rather than directly targeting viral genes has the
added advantage that it is less likely to lead to the emergence of
mutant virus. This anti-WNV strategy may also be combined with
other currently available supportive measures, such as IFN
therapy, in order to reap better clinical outcomes.
Identification of a major cellular source of IL-10 during WNV
infection inmicewould, inprinciple, provide a more accurate target
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found that CD4
+ T cells produce a significant amount of IL-10 and
may be a major cellular source of IL-10 in vivo during WNV
infection. Our data also indicate that macrophages produce IL-10
when exposed to WNV ex vivo (Figure 1 A and B), which is
consistent with in vivo results showing that CD11b
+ macrophages
produce low levels of IL-10. It is becoming evident that naturally
occurring or adaptive CD4
+ regulatory T cells produce copious
amounts of IL-10 in different disease models [38,39,42]. Further
studies are warranted to identify which CD4
+ T cell subset is a
major IL-10 producing cell during WNV infection in vivo. However,
it should be noted that such a therapeutic strategy would need to be
carefully titrated, as IL-10 signaling can also be beneficial by
limiting extensive immunopathological damage resulting from
uncontrolled Th1 or lymphokine-responsive T effector cell
responses. Thus, while modulation of IL-10 signaling may be a
means to enhance anti-pathogen immunity or limit immunopa-
thology, this must be approached with caution to avoid tipping the
balance too far in either direction. It is worth noting that we did not
observe any overt immunopathology in IL-10
2/2 mice during
WNV infection, and surviving IL-10
2/2 mice appeared active and
healthy at the end of our infection experiments. It may be feasible to
temporally block or reduce IL-10 signaling in the early phase of
acute WNV infection to stimulate the patient’s anti-viral immune
responses without causing severe immunopathological side-effects.
Of course, further pre-clinical studies focused on blocking IL-10
signaling as a therapeutic strategy against WNV infection would
need to be explored both in terms of safety and efficacy before
moving forward into clinical trials.
Materials and Methods
Experimental animals and virus infection
C57BL/6, IL-10
2/2and RAG1
2/2 mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). IL-10-GFP knock-in
tiger mice were generated in the laboratory of R. A. Flavell as
previously described [40], and were bred as heterozygotes. We
performed all experiments on 7–8 week-old mice, and mouse
groups were rigorously age- and sex-matched for each infection
experiment. West Nile viral isolate 2471 [64] used in these studies
was propagated one time in Vero cells and titered in a Vero cell
plaque-formation assay. We inoculated mice i.p. with LD50 (2,000
pfu) of WNV isolate 2741 in 100 ml of PBS with 5% gelatin. We
performed footpad inoculation by injecting 100 pfu of WNV
diluted in 50 ml PBS with 1% heat-inactivated fetal bovine serum
(FBS) and conducted intracranial inoculation by injecting 20 pfu of
WNV in 20 ml PBS with 1% FBS according to a previous report
[32]. We observed mice for up to 21 days after infection and
checked them twice daily for morbidity (including lethargy,
anorexia, and difficulty ambulating) and mortality. All animal
experimental protocols were approved by the Yale University
Institutional Animal Care & Use Committee. All animal infection
experiments were performed in a Bio-safety Level 3 animal facility,
according to the regulations of Yale University.
Cytokine PCR array
One million peritoneal thioglycollate-elicited macrophages were
prepared from wild-type or IL-10
2/2 mice and challenged with
WNV isolate 2741 (MOI=1) in 6-well culture plates in 2 ml of
medium and incubated in a 37uC, 5% CO2 incubator. Macro-
phages were collected at 24 h after washes with PBS for total RNA
extraction by Qiagen RNeasy Mini kit (Valencia, CA). The
RT
2Profiler
TM PCR Array kits were purchased from SuperArray
Bioscience Corporation (Frederick, MD), and all assay procedures
were conducted in accordance with the kit user manual. Briefly, one
microgram of total RNA from IL-10
2/2 or wild-type macrophages
wastranscribed into firststrandcDNA and loadedinto 96-wellPCR
array plates with 25 mL Q-PCR master mix per well. After
performing Q-PCR, resulting threshold cycle values (Ct) for all
genes were exported into the company-provided data analysis
template Excel files for comparison of gene expression between IL-
10
2/2 and wild-type macrophages. The Q-PCR array experiments
were repeated three times with similar results.
Q-PCR and plaque-formation assay
Total RNA was extracted from macrophages, blood, spleen and
brain tissue using the RNeasy kit (Qiagen, Valencia, CA). RNA
was used to synthesize cDNA by the AffinityScript Multi
Temperature cDNA synthesis kit (Stratagene, La Jolla, CA).
WNV-specific RNA was quantified using a Q-PCR technique as
we previously reported [65]. Cytokine gene and viral gene copy
number were expressed as a ratio to cellular b-actin cDNA copies
measured by Q-PCR. The ratio of the amount of amplified gene
compared with the amount of b-actin cDNA represented the
relative levels in each sample. Plaque-formation assay procedures
were carried out according to our previous report [66].
Confocal microscopy
Mice were sacrificed under isofluorane anesthesia and transcar-
dially perfused with 60 ml of ice-cold PBS. Brains were rapidly
isolated and immersion fixed in 4% PFA in PBS overnight at 4uC,
and cryoprotected in a graded series of sucrose (10%, 20%, and
30%, each overnight at 4uC). Para-median sagittal sections were
cut at 25 mm using a cryostat. Tissue sections were PAP pen
(Zymed Laboratories, South San Francisco, CA) applied and pre-
blocked in serum-free protein block (Dakocytomation, Denmark)
for 30 min at ambient temperature. Sections were then labeled
overnight at 4uC with various combinations of primary antibodies
against CD11b (1:200, Serotec, Raleigh, NC), CD45 (1:200,
Serotec), MAP2 (1:500, Invitrogen) and/or WNV antigen (from J.
F. Anderson; 1:250). After three rinses in PBS, sections were
labeled with appropriate secondary antibodies conjugated with
AlexaFluor488,- 594, and/or -647 for 1 h at ambient temperature.
Following three additional rinses in PBS sections were mounted in
fluorescence mounting medium (ProLong Gold, Invitrogen).
Images were acquired in independent channels using a Nikon
C1 Eclipse laser scanning confocal microscope.
Interferon bioassay
Type I IFN activity in medium or plasma was detected and
quantified using an EMCV bioassay of L929 cells as described [67].
Briefly, serially diluted samples were applied to monolayers of L929
cells (2610
6 cells/well) in DMEM containing 10% FBS in 96-well
plates. Following incubation for 14 h at 37uC, cells were infected
with EMCV. Cells were inspected for cytopathic effects, and 7 h
p.i., IFN-mediated protection was assayed using a CellTiter 96
aqueous cell proliferation assay (Promega, Madison, WI). The
percentage of protected cells was calculated as described [68],
according to the following formula: (optical density at 492 nm
[OD492] of plasma or supernatant-treated EMCV-infected cells/
(OD492 of non-EMCV-infected cells 2 OD492 of EMCV-infected
cells)/OD492 of non-EMCV-infected cells)6100%).
Cell preparation and culture conditions
Mouse peritoneal macrophages were elicited by i.p. injection with
1 ml of thioglycollate medium (BD BBL
TM,F r a n k l i nL a k e s ,N J )a n d
macrophages were collected 3 days later and cultured in DMEM
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from naı ¨ve or WNV-infected mice at selected time points and
cultured in RPMI 1640 medium and infected by WNV (MOI=0.5)
or stimulated with 50 ng/mlof PMA (Sigma-Aldrich, St. Louis,MO)
or WNV NS4b peptide (SSVWNTATTAI, 1.0 mg/ml). Cell
supernatants were collected for cytokine ELISA analysis using kits
purchased from R&D Systems (Minneapolis, MN).
In vivo monoclonal antibody treatment
Seven-week-old female C57BL/6 mice were i.p. injected with
250 mg of mouse anti-IL10r (clone 1B1.3a) or isotype-matched
IgG1 (clone R3-34) antibodies in 100 ml of PBS one day prior to
WNV infection. Anti-IL10r mAb and isotype control antibodies
were purchased from BD Bioscience Pharmingen (San Diego, CA).
In anti-IL-10 mAb immunotherapeutic experiments, two doses of
200 mg antibody (clone JES052A5) or isotype control IgG1 (clone
43414, R&D Systems) in 100 ml PBS were injected i.p. daily, with
the first dose starting on either day 2 or 4 post-WNV infection.
Extracellular and intracellular immunostaining
To measure IFN-c production, splenocytes from WNV-infected
mice were isolated and cultured under one of two conditions. Half
of the samples were incubated at 3610
6 cells/tube at room
temperature with no exogenous stimulation for 4 h and Golgi-plug
(BD Bioscience Pharmingen, 1.0 mg/ml) was added for the final
2 h (BD Bioscience Pharmingen). We used conditions previously
described as optimal for spontaneous accumulation of cytokines
after removal from the host [69]. The remaining samples were
stimulated at 3610
6 cells/tube with 50 ng/ml of PMA (Sigma-
Aldrich) or with 1.0 mg/ml of WNV NS4b peptide and 500 ng/ml
of ionomycin (Sigma-Aldrich) for 4 h at 37uC and Golgi-plug
(1.0 mg/ml) was added during the final 2 h. Cells were then
harvested and stained with the following cell surface antibodies (all
were obtained from BD Biosciences Pharmingen): CD3 (clone
500A2), CD4 (clone RM4-5), CD8 (clone 53-6.7), CD11b (M1/
70), or CD19 (1D3) and fixed in 4% PFA. Cells were then
permeabilized with 0.5% saponin before adding FITC-conjugated
anti-IFN-c mAb (BD Bioscience Pharmingen, CA) or isotype-
matched control FITC-conjugated rat IgG1 for intracellular
staining.
Splenocyte adoptive transfer
Splenic single cell suspensions were prepared from naı ¨ve
C57BL/6 or IL-10
2/2 mice and CD4
+ T cells were positively
selected using anti-mouse CD4 (L3T4)-conjugated microbeads
(Miltenyi Biotec, Auburn, CA) according to the manufacturer’s
instructions and the purity of eluted cells was assessed by flow
cytometry analysis. RAG1
2/2 mice received 1610
7 CD4
+ T cells
(.98% purity) in 200 ml of PBS per mouse or PBS alone as
control.
Statistical analysis
We calculated standard errors of the means (SEM) and analyzed
data by non-paired Student’s t-test for single mean comparisons.
We performed survival curve comparisons using the log-rank test
(GraphPad Prism 4.0, La Jolla, CA). p,0.05 was considered as
statistically significant for all analyses.
Accession numbers
IL-10 (MGI 96537, PF 00726); WNVE (AF 206518); IFN-a (M
68944); IFN-b (NM 010510); IFN-c (NM 008337); TNF-a (MGI
104798); IL-12/23 p40 (MGI 96540); Rag1 (MGI 97848); Actb
(MGI 87904).
Supporting Information
Figure S1 Reduced brain WNV infection and CD11b
+ innate
immune cells in IL-10
2/2 mice. Perfused brains were isolated on
day 7 p.i., and WNV antigen (green signal), CD11b (red signal)
and neurons (MAP2, blue signal) were detected by confocal
microscopy. These images represent 9 mice per group in 3
independent experiments, in which similar results were obtained.
Found at: doi:10.1371/journal.ppat.1000610.s001 (5.16 MB PDF)
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